What the Strüngmann brothers are funding now — Antheia, AAVantgarde Bio, Doctolib, Immatics, Tubulis — and what it signals about the next decade of DACH biotech.

Why Athos Service — the Strüngmann brothers' Munich family office — outperforms US-style venture capital on deep-tech bets like BioNTech.

The 2005 Novartis-Hexal deal made the Strüngmanns' fortune — but more importantly, it taught them how to recycle one exit into the next BioNTech.

From Hexal's €5.65B Novartis exit to BioNTech's $50B+ peak — how Andreas and Thomas Strüngmann built the architect-class behind DACH biotech. Inside the Athos Service playbook.

Founders who reach platform-scale success face a structural problem: the company they built can no longer execute the science they want to do. Şahin and Türeci's planned 2026 spin into a new mRNA company is the engineered answer — separate frontier research from commercial discipline, retain agency, keep economic exposure through BioNTech's planned minority stake. It is the rarest move in European deep tech because it requires founders who own the cap table to design it. Intr

The popular framing that BioNTech "got lucky with COVID" collapses under the timeline. The company was incorporated in Mainz in 2008 with cancer immunotherapy as the founding thesis, was anchored by Strüngmann patient capital years before any pandemic, and had already attracted a 2019 Gates Foundation investment for HIV and tuberculosis programs. The vaccine was the visible breakthrough; the bet was twelve years old. Introduction The anchor piece argues that BioNTech is a pow

Uğur Şahin and Özlem Türeci's planned 2026 transition out of BioNTech management to lead a new mRNA company is a rare European founder act-two — engineered with cap-table control, BioNTech as minority stakeholder, and patient German capital underneath. The vaccine was the visible breakthrough; the founder pattern is what DACH should be studying.